Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
April 30 2024 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced it
will report financial results for the first quarter 2024
on Tuesday, May 7, 2024, after the closing of
the U.S. financial markets.
Management will conduct a conference call at
5:00 p.m. ET on the same day to provide a corporate update.
The conference call will be webcast live over the internet and can
be accessed by logging into the “Investors” page of
the Aclaris Therapeutics website, www.aclaristx.com,
prior to the event. The webcast will be archived for at least 30
days on the Aclaris website.
About Aclaris Therapeutics,
Inc.
Aclaris Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing a pipeline of novel drug
candidates to address the needs of patients with
immuno-inflammatory diseases who lack satisfactory treatment
options. The company has a multi-stage portfolio of drug candidates
powered by a robust R&D engine exploring protein kinase
regulation. For additional information, please visit
www.aclaristx.com.
Aclaris Therapeutics
Contact:
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From May 2024 to Jun 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2023 to Jun 2024